Triclosan Antiseptic Category I Status Requested By CIBA
This article was originally published in The Rose Sheet
Executive Summary
FDA should consider new safety data supporting Category I (safe and effective) status for triclosan in the OTC Tentative Final Monograph for Health Care Antiseptic Drug Products, CIBA Specialty Chemicals and an alliance of six triclosan manufacturers/ marketers state in a Sept. 13 citizen petition.
You may also be interested in...
Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”
Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”
Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application